GeoVax Labs (GOVX) Stock Price, News & Analysis

Company Overview

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses.

GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases. The company has also pursued immunotherapy approaches for cancer, including candidates intended to stimulate immune responses against tumor-associated targets.

Founded in 2001 and headquartered in Atlanta, Georgia, GeoVax conducts research and development through collaborations with government agencies, academic institutions, and industry partners. The company’s programs are primarily in preclinical or clinical development, and its lead programs and geographic reach may change as studies and partnerships advance. GeoVax is led by David Dodd, who serves as chairman and chief executive officer.

Key Stats

• Today's Range: $0.14 to $0.16
• 50-Day Range: $0.16 to $0.72
• 52-Week Range: $0.14 to $13.44
• Volume: 363,052 shs
• Average Volume: 345,026 shs
• Market Capitalization: $1.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $150.00
• Consensus Rating: Hold

GeoVax Labs Stock Analysis - MarketRank™

GeoVax Labs scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

GeoVax Labs has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

GeoVax Labs has a consensus price target of $150.00, representing about 93,650.0% upside from its current price of $0.16.

Amount of Analyst Coverage

GeoVax Labs has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GeoVax Labs are expected to grow in the coming year, from ($4.94) to ($2.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeoVax Labs is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeoVax Labs is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeoVax Labs has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.67% of the float of GeoVax Labs has been sold short.

Short Interest Ratio / Days to Cover

GeoVax Labs has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeoVax Labs has recently decreased by 4.10%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeoVax Labs does not currently pay a dividend.

Dividend Growth

GeoVax Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for GOVX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GeoVax Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.22% of the stock of GeoVax Labs is held by insiders.

Percentage Held by Institutions

6.09% of the stock of GeoVax Labs is held by institutions.

Company Calendar

• Last Earnings: 7/27/2026
• Today: 11/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GOVX
• CIK: 832489
• Web: www.geovax.com
• Phone: (678) 384-7220
• Fax: 678-384-7281
• Employees: 19
• Year Founded: 2001

Price Target and Rating

• Average Price Target for GeoVax Labs: $150.00
• High Price Target: $150.00
• Low Price Target: $150.00
• Potential Upside/Downside: +93,650.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.47 million
• Net Margins: N/A
• Pretax Margin: -2,508.10%
• Return on Equity: -743.64%
• Return on Assets: -394.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.54
• Quick Ratio: 1.54

Sales & Book Value

• Annual Sales: $2.49 million
• Price / Sales: 0.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.21 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 7,370,000
• Free Float: 7,353,000
• Market Cap: $1.18 million
• Optionable: Not Optionable
• Beta: 3.85